Novocure fails PhIII in platinum-resistant ovarian cancer

Paul Schloesser

Associate Editor

Novocure’s ovarian cancer treatment failed to meet the primary endpoint of overall survival in a Phase III trial, sending the New Jersey biotech’s stock price …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novocure fails PhIII in platinum-resistant ovarian cancer

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Novo­cure fails PhI­II in plat­inum-re­sis­tant ovar­i­an can­cer

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novocure fails PhIII in platinum-resistant ovarian cancer